Key Factors to Consider Before Investing in Welltower (WELL)

Shares of Specialty Real Estate Investment Trust company Welltower jumped 2.4% today. With many investors piling into WELL without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

  • Welltower has moved 27.0% over the last year, and the S&P 500 logged a change of 13.0%

  • WELL has an average analyst rating of buy and is -2.87% away from its mean target price of $90.13 per share

  • Its trailing earnings per share (EPS) is $0.53

  • Welltower has a trailing 12 month Price to Earnings (P/E) ratio of 165.2 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $1.23 and its forward P/E ratio is 71.2

  • The company has a Price to Book (P/B) ratio of 2.03 in contrast to the S&P 500's average ratio of 2.95

  • Welltower is part of the Real Estate sector, which has an average P/E ratio of 24.81 and an average P/B of 2.24

  • The company has a free cash flow of $2.47 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • Welltower Inc. (NYSE:WELL), a real estate investment trust ("REIT") and S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. Welltower invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people's wellness and overall health care experience. Welltower, owns interests in properties concentrated in major, high-growth markets in the United States, Canada and the United Kingdom, consisting of seniors housing and post-acute communities and outpatient medical properties.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.